PMID- 22053972
OWN - NLM
STAT- MEDLINE
DCOM- 20120315
LR  - 20211021
IS  - 1563-5244 (Electronic)
IS  - 0883-0185 (Print)
IS  - 0883-0185 (Linking)
VI  - 30
IP  - 5-6
DP  - 2011 Oct-Dec
TI  - TCR-like biomolecules target peptide/MHC Class I complexes on the surface of 
      infected and cancerous cells.
PG  - 328-40
LID - 10.3109/08830185.2011.604880 [doi]
AB  - The human leukocyte antigen (HLA; also called major histocompatibility, or MHC) 
      class I system presents peptides that distinguish healthy from diseased cells. 
      Therefore, the discovery of peptide/MHC class I markers can provide highly 
      specific targets for immunotherapy. Over the course of almost two decades, 
      various strategies have been used, with mixed success, to produce antibodies that 
      have recognition specificity for unique peptide/MHC class I complexes that mark 
      infected and cancerous cells. Using these antibody reagents, novel peptide/MHC 
      class I targets have been directly validated on diseased cells and new insight 
      has been gained into the mechanisms of antigen presentation. More recently, these 
      antibodies have shown promise for clinical applications such as therapeutic 
      targeting of cancerous and infected cells and diagnosis and imaging of diseased 
      cells. In this review, the authors comprehensively describe the methods used to 
      identify disease-specific peptide/MHC class I epitopes and generate antibodies to 
      these markers. Finally, they offer several examples that illustrate the promise 
      of using these antibodies as anti-cancer agents.
FAU - Weidanz, Jon A
AU  - Weidanz JA
AD  - Department of Biomedical Sciences and Center for Immunotherapeutic Research, 
      Texas Tech University Health Sciences Center, 1718 Pine, Abilene, TX 79601, USA. 
      jon.weidanz@ttuhsc.edu
FAU - Hawkins, Oriana
AU  - Hawkins O
FAU - Verma, Bhavna
AU  - Verma B
FAU - Hildebrand, William H
AU  - Hildebrand WH
LA  - eng
GR  - R01 AI090672/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int Rev Immunol
JT  - International reviews of immunology
JID - 8712260
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*immunology
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - Histocompatibility Antigens Class I/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Peptides/*immunology/metabolism
MH  - Receptors, Antigen, T-Cell/*immunology/metabolism
PMC - PMC3405915
MID - NIHMS387579
EDAT- 2011/11/08 06:00
MHDA- 2012/03/16 06:00
PMCR- 2012/07/26
CRDT- 2011/11/08 06:00
PHST- 2011/11/08 06:00 [entrez]
PHST- 2011/11/08 06:00 [pubmed]
PHST- 2012/03/16 06:00 [medline]
PHST- 2012/07/26 00:00 [pmc-release]
AID - 10.3109/08830185.2011.604880 [doi]
PST - ppublish
SO  - Int Rev Immunol. 2011 Oct-Dec;30(5-6):328-40. doi: 10.3109/08830185.2011.604880.